Stifel lowered the firm’s price target on uniQure (QURE) to $40 from $50 and keeps a Buy rating on the shares. The firm “refreshed diligence” on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target lowered to $33 from $60 at Mizuho
- These 3 Under-the-Radar Stocks Have Triple-Digit Upside Potential – 12/5/2025
- Midday Fly By: Meta to slash metaverse spending, Salesforce posts Q3 beat
- Video: Salesforce rises, Snowflake dips after quarterly reports
- uniQure Faces Setback in Gene Therapy Approval